Chimeric antigen receptor (CAR) T cell therapy is a new and in some cases highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system. This promising treatment comes at a cost, however: ...
Jun 23, 2020
0
0
Chimeric antigen receptor (CAR) T cells have transformed the treatment of refractory blood cancers. These genetically engineered immune cells seek out and destroy cancer cells with precision. Now, scientists at Memorial Sloan ...
Jun 17, 2020
0
142
Developing a vaccine is difficult at the best of times, but rarely have we been in a situation where basic knowledge about a virus has to be acquired so directly alongside the race to eradicate it. To understand how difficult ...
Jun 11, 2020
0
10
For much of the last decade, Dr. David Rawlings, director of Seattle Children's Research Institute's Center for Immunity and Immunotherapies, has dreamed of developing a therapy for children with type 1 diabetes that doesn't ...
Jun 3, 2020
0
887
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial ...
May 29, 2020
0
1
Adoptive T cell therapies, including chimeric antigen receptor (CAR) T cell therapy, which use genetically engineered killer immune T cells, are emerging forms of immunotherapy that redirect the immune system to target cancer.
May 19, 2020
0
80
The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School (Duke-NUS), as a potential therapy for controlling infectious diseases, ...
Apr 21, 2020
0
182
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric ...
Apr 1, 2020
0
13
Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Perelman School of Medicine at the University of Pennsylvania ...
Mar 23, 2020
0
396
In 1998, when Timothy Hla, Ph.D., and his colleagues identified and cloned the receptor for sphingosine-1-phosphate (S1P), it generated a lot of excitement. S1P, a lipid originally discovered in the 1960s, was known to play ...
Mar 11, 2020
0
79
